Neurocrine's Schizophrenia Drug Shows 7.5 Point Improvement in Phase 2 Trial; Shares Drop 15.6%

Aug 28, 2024, 11:33 AM

Neurocrine Biosciences has announced positive results from a mid-stage Phase 2 study of its experimental drug NBI-1117568 for treating schizophrenia in adults. The study achieved its main goal, showing a 7.5 point improvement on the PANSS score with a 20 mg daily dose, which was statistically significant. However, no improvement was observed with higher doses. Despite the positive outcome, the company's shares have dropped by 15.6% in pre-market trading as investors reacted to the mixed results of the trial.